UK's hVIVO gains on $14.7 mln RSV contract

hVIVO

10/12/2024 09:13

** Shares of contract research organization hVIVO  HVO.L  up
4.7% at 22.25p
    ** Co signs 11.5 mln pounds ($14.66 mln) Respiratory
Syncytial Virus (RSV) contract with an existing global pharma
client
    ** Phase 2A trial to commence in H2 2025, sees revenue
recognition across 2025 and 2026
    ** Reaffirms FY 2024 rev guidance of 62 mln pounds, sees
annual EBITDA margins at upper end of market views 
    ** As of last close, stock down ~6.27%, YTD
    
($1 = 0.7844 pounds)

 (Reporting by Ankita Bora in Bengaluru)
 ((Ankita.Bora@thomsonreuters.com))